Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8454707 | 0.80 | AOC3 (0.44) | CA1CA9ALDH1A1POLB | |
| SCHEMBL21391528 | 0.79 | CA12 (0.40) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL30514294 | 0.79 | CA12 (0.40) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL15242469 | 0.75 | CA1 (0.42) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL19745616 | 0.74 | CA12 (0.41) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL29306881 | 0.74 | CA12 (0.40) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL343105 | 0.73 | CA12 (0.40) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL21391571 | 0.73 | ALOX15 (0.33) | ALOX15 | |
| SCHEMBL7706827 | 0.73 | CA1 (0.50) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL26304030 | 0.72 | ACP3 (0.46) | ALOX15ALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281092-B2 | Compound or salt thereof, composition, chemiluminescence method, method for measuring chemiluminescence signal, reagent, reagent kit, and method for assaying analyte | SYSMEX CORPORATION (JP) | 2025-04-22 | — | — | US | disclosed |
| WO-2024147125-A1 | CYCLOBUTYL-SUBSTITUTED PHENOXY-DIOXETANES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-07-11 | — | — | WO | disclosed |
| US-20230242499-A1 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | SYSMEX CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230242499-A1 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | SYSMEX CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| EP-4219651-A1 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | SYSMEX CORPORATION (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-02-17 | — | — | US | disclosed |
| US-11179482-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2021-11-23 | — | — | US | disclosed |
| EP-3408349-B1 | CHEMILUMINESCENT FLUOROPHOR-LINKED ADAMANTYLENE-DIOXETANE PROBES AS DIAGNOSTICS OR IN-VIVO IMAGING SENSORS | UNIV RAMOT (IL) | 2021-03-31 | — | — | EP | disclosed |
| US-20200237932-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-07-30 | — | — | US | disclosed |
| US-10660974-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-05-26 | — | — | US | disclosed |
| US-20190290787-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660974-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | DAXX, DCAF15, DCAF1 | CA12 293/4885CA1 1716/4885CA9 568/4885 |
| US-20200237932-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, CDY1; CDY1B | CA12 59/4885CA1 504/4885CA9 370/4885 |
| US-12281092-B2 | Compound or salt thereof, composition, chemiluminescence method, method for measuring chemiluminescence signal, reagent, reagent kit, and method for assaying analyte | JAK2, MPO, PEAK1 | CA12 67/4885CA1 267/4885CA9 11/4885 |
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, CDY1; CDY1B | CA12 59/4885CA1 504/4885CA9 370/4885 |
| US-11179482-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | DAXX, DCAF15, CDY1; CDY1B | CA12 59/4885CA1 504/4885CA9 370/4885 |
| US-20190290787-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, DCAF1 | CA12 293/4885CA1 1716/4885CA9 568/4885 |
| US-20230242499-A1 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | JAK2, MPO, PEAK1 | CA12 67/4885CA1 267/4885CA9 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.